These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 16940091)
41. Cyclosporine inhibits mouse cytomegalovirus infection via a cyclophilin-dependent pathway specifically in neural stem/progenitor cells. Kawasaki H; Mocarski ES; Kosugi I; Tsutsui Y J Virol; 2007 Sep; 81(17):9013-23. PubMed ID: 17553872 [TBL] [Abstract][Full Text] [Related]
42. Hepatitis C virus replication is inhibited by 22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol (ME3738) through enhancing interferon-beta. Hiasa Y; Kuzuhara H; Tokumoto Y; Konishi I; Yamashita N; Matsuura B; Michitaka K; Chung RT; Onji M Hepatology; 2008 Jul; 48(1):59-69. PubMed ID: 18459156 [TBL] [Abstract][Full Text] [Related]
43. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. Chatterji U; Bobardt M; Selvarajah S; Yang F; Tang H; Sakamoto N; Vuagniaux G; Parkinson T; Gallay P J Biol Chem; 2009 Jun; 284(25):16998-17005. PubMed ID: 19380579 [TBL] [Abstract][Full Text] [Related]
45. In vitro infection of immortalized primary hepatocytes by HCV genotype 4a and inhibition of virus replication by cyclosporin. El-Farrash MA; Aly HH; Watashi K; Hijikata M; Egawa H; Shimotohno K Microbiol Immunol; 2007; 51(1):127-33. PubMed ID: 17237608 [TBL] [Abstract][Full Text] [Related]
46. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. Yang F; Robotham JM; Nelson HB; Irsigler A; Kenworthy R; Tang H J Virol; 2008 Jun; 82(11):5269-78. PubMed ID: 18385230 [TBL] [Abstract][Full Text] [Related]
47. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Henry SD; Metselaar HJ; Lonsdale RC; Kok A; Haagmans BL; Tilanus HW; van der Laan LJ Gastroenterology; 2006 Nov; 131(5):1452-62. PubMed ID: 17101321 [TBL] [Abstract][Full Text] [Related]
48. Suppression of hepatitis C virus replication by protein kinase C-related kinase 2 inhibitors that block phosphorylation of viral RNA polymerase. Kim SJ; Kim JH; Sun JM; Kim MG; Oh JW J Viral Hepat; 2009 Oct; 16(10):697-704. PubMed ID: 19243496 [TBL] [Abstract][Full Text] [Related]
49. Cyclophilin inhibitors for the treatment of HCV infection. Fischer G; Gallay P; Hopkins S Curr Opin Investig Drugs; 2010 Aug; 11(8):911-8. PubMed ID: 20721833 [TBL] [Abstract][Full Text] [Related]
50. Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication. Esser-Nobis K; Harak C; Schult P; Kusov Y; Lohmann V Hepatology; 2015 Aug; 62(2):397-408. PubMed ID: 25866017 [TBL] [Abstract][Full Text] [Related]
51. Cyclophilin inhibitors in hepatitis C viral infection. Flisiak R; Dumont JM; Crabbé R Expert Opin Investig Drugs; 2007 Sep; 16(9):1345-54. PubMed ID: 17714021 [TBL] [Abstract][Full Text] [Related]
52. Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A. Fernandes F; Ansari IU; Striker R PLoS One; 2010 Mar; 5(3):e9815. PubMed ID: 20352119 [TBL] [Abstract][Full Text] [Related]
53. [Current approaches for developing new anti-HCV agents and analyses of HCV replication using anti-HCV agents]. Watashi K; Shimotohno K Uirusu; 2005 Jun; 55(1):105-10. PubMed ID: 16308536 [TBL] [Abstract][Full Text] [Related]
54. Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition. Fu J; Tjandra M; Becker C; Bednarczyk D; Capparelli M; Elling R; Hanna I; Fujimoto R; Furegati M; Karur S; Kasprzyk T; Knapp M; Leung K; Li X; Lu P; Mergo W; Miault C; Ng S; Parker D; Peng Y; Roggo S; Rivkin A; Simmons RL; Wang M; Wiedmann B; Weiss AH; Xiao L; Xie L; Xu W; Yifru A; Yang S; Zhou B; Sweeney ZK J Med Chem; 2014 Oct; 57(20):8503-16. PubMed ID: 25310383 [TBL] [Abstract][Full Text] [Related]
55. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Hopkins S; Scorneaux B; Huang Z; Murray MG; Wring S; Smitley C; Harris R; Erdmann F; Fischer G; Ribeill Y Antimicrob Agents Chemother; 2010 Feb; 54(2):660-72. PubMed ID: 19933795 [TBL] [Abstract][Full Text] [Related]
56. Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication. Ma-Lauer Y; Zheng Y; Malešević M; von Brunn B; Fischer G; von Brunn A Antiviral Res; 2020 Jan; 173():104620. PubMed ID: 31634494 [TBL] [Abstract][Full Text] [Related]
57. From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds. Sweeney ZK; Fu J; Wiedmann B J Med Chem; 2014 Sep; 57(17):7145-59. PubMed ID: 24831536 [TBL] [Abstract][Full Text] [Related]
58. Treating hepatitis C: can you teach old dogs new tricks? Rice CM; You S Hepatology; 2005 Dec; 42(6):1455-8. PubMed ID: 16317665 [TBL] [Abstract][Full Text] [Related]
59. An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C. Crabbé R; Vuagniaux G; Dumont JM; Nicolas-Métral V; Marfurt J; Novaroli L Expert Opin Investig Drugs; 2009 Feb; 18(2):211-20. PubMed ID: 19236267 [TBL] [Abstract][Full Text] [Related]
60. Discovery of a novel 9-position modified second-generation anti-HCV candidate via bioconversion and semi-synthesis of FR901459. Makino T; Ishida J; Yamanaka T; Ohki H; Uchida M; Sawada M; Barrett D Bioorg Med Chem Lett; 2020 Sep; 30(18):127423. PubMed ID: 32731088 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]